Leerink Partnrs Analysts Reduce Earnings Estimates for BBIO

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Investment analysts at Leerink Partnrs lowered their Q4 2024 earnings per share estimates for shares of BridgeBio Pharma in a research report issued on Tuesday, January 21st. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($1.07) per share for the quarter, down from their previous estimate of ($1.06). The consensus estimate for BridgeBio Pharma's current full-year earnings is ($2.56) per share. Leerink Partnrs also issued estimates for BridgeBio Pharma's FY2025 earnings at ($2.77) EPS, FY2026 earnings at ($1.00) EPS, FY2027 earnings at $1.61 EPS, FY2028 earnings at $4.55 EPS and FY2029 earnings at $5.78 EPS.

Several other equities research analysts also recently weighed in on the stock. Evercore ISI upped their target price on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the stock an "outperform" rating in a research note on Monday, December 23rd. Bank of America increased their price objective on BridgeBio Pharma from $42.00 to $45.00 and gave the company a "buy" rating in a research note on Monday, November 25th. HC Wainwright reissued a "buy" rating and set a $49.00 target price on shares of BridgeBio Pharma in a research note on Monday, December 16th. Oppenheimer assumed coverage on BridgeBio Pharma in a research report on Thursday, October 3rd. They issued a "market perform" rating on the stock. Finally, Scotiabank boosted their price objective on BridgeBio Pharma from $45.00 to $48.00 and gave the stock a "sector outperform" rating in a research report on Monday, November 25th. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $48.08.

BridgeBio Pharma Stock Up 3.5 %

NASDAQ:BBIO traded up $1.24 on Thursday, reaching $37.08. 676,601 shares of the company's stock were exchanged, compared to its average volume of 3,069,696. The firm has a market capitalization of $7.01 billion, a price-to-earnings ratio of -15.48 and a beta of 1.05. BridgeBio Pharma has a 52-week low of $21.62 and a 52-week high of $41.04. The business has a fifty day moving average of $28.27 and a 200-day moving average of $26.74.

Insiders Place Their Bets

In other news, CFO Brian C. Stephenson sold 4,156 shares of the stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $22.41, for a total transaction of $93,135.96. Following the completion of the sale, the chief financial officer now owns 93,758 shares in the company, valued at approximately $2,101,116.78. This represents a 4.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Neil Kumar sold 27,389 shares of the business's stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $22.41, for a total value of $613,787.49. Following the completion of the transaction, the chief executive officer now owns 4,897,443 shares in the company, valued at $109,751,697.63. This trade represents a 0.56 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 24.66% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Values First Advisors Inc. acquired a new stake in shares of BridgeBio Pharma in the 3rd quarter worth $57,000. CWM LLC increased its position in BridgeBio Pharma by 132.9% during the 3rd quarter. CWM LLC now owns 3,442 shares of the company's stock worth $88,000 after purchasing an additional 1,964 shares during the period. Advisors Asset Management Inc. lifted its holdings in shares of BridgeBio Pharma by 56.1% in the 3rd quarter. Advisors Asset Management Inc. now owns 4,576 shares of the company's stock valued at $117,000 after buying an additional 1,645 shares during the period. Amalgamated Bank boosted its stake in shares of BridgeBio Pharma by 24.7% in the second quarter. Amalgamated Bank now owns 4,863 shares of the company's stock valued at $123,000 after buying an additional 962 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its position in BridgeBio Pharma by 17.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 5,322 shares of the company's stock worth $135,000 after acquiring an additional 801 shares in the last quarter. Institutional investors and hedge funds own 99.85% of the company's stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.